Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28310972 | 0.92 | LMNA (0.31) | MGLL | |
| SCHEMBL16478530 | 0.87 | — | — | |
| SCHEMBL24152402 | 0.80 | MGLL (0.30) | MGLL | |
| SCHEMBL30755128 | 0.80 | MGLL (0.30) | MGLL | |
| SCHEMBL13883935 | 0.79 | THRB (0.36) | — | |
| SCHEMBL11251868 | 0.78 | MGLL (0.36) | MGLL | |
| SCHEMBL17777287 | 0.78 | MGLL (0.33) | MGLL | |
| SCHEMBL6699078 | 0.78 | MGLL (0.33) | MGLL | |
| SCHEMBL2570463 | 0.78 | MGLL (0.33) | MGLL | |
| SCHEMBL14596780 | 0.77 | THRB (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081372-A1 | PROCESSES FOR THE PREPARATION OF THE AGENT-LINKER CONJUGATE CL2A-SN-38 AND THE IMMUNOCONJUGATES SACITUZUMAB GOVITECAN AND LABETUZUMAB GOVETICAN | GILEAD SCIENCES, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| CN-111187284-A | Preparation method of cefaclor | 赵俊瑶 | 2020-05-22 | — | — | CN | claimed |
| CN-111138994-A | Removable polypropylene label material for mobile phone cover and preparation method thereof | 深圳昌茂粘胶新材料有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-111057071-A | Preparation method of cefalexin | 刘思思 | 2020-04-24 | — | — | CN | claimed |
| EP-2315747-B1 | METHODS AND COMPOSITIONS RELATING TO SYNTHETIC BETA-1,6 GLUCOSAMINE OLIGOSACCHARIDES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2017-12-06 | — | — | EP | claimed |
| EP-2985286-B1 | MIDBODY OF TICAGRELOR AND PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR TICAGRELOR | JIANGSU HENGRUI MEDICINE CO (CN) | 2017-10-11 | — | — | EP | claimed |
| EP-2682466-B1 | siRNA conjugate and preparation method thereof | BIONEER CORP (KR) | 2016-07-20 | — | — | EP | claimed |
| CN-102159540-B | Methods and compositions related to synthetic beta-1, 6 glucosamine oligosaccharides | THE BRIGHAM AND WOMEN'S HOSPITAL INC. (US) | 2015-08-12 | — | — | CN | claimed |
| US-20140350233-A1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | BIONEER CORPORATION (KR) | 2014-11-27 | — | — | US | claimed |
| EP-2682466-A1 | siRNA conjugate and preparation method thereof | Bioneer Corporation (KR) | 2014-01-08 | — | — | EP | claimed |
| CN-102276576-B | Benzamide compound and preparation method thereof | UNIV NORTHWESTERN POLYTECHNIC | 2013-08-14 | — | — | CN | claimed |
| EP-2463371-A2 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | Bioneer Corporation (KR) | 2012-06-13 | — | — | EP | claimed |
| US-20120108803-A1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | BIONEER CORPORATION (KR) | 2012-05-03 | — | — | US | claimed |
| CN-102276576-A | benzamide compound and preparation method thereof | — | 2011-12-14 | — | — | CN | claimed |
| US-12629425-B2 | Progammable polymeric drugs | Sony Group Corporation (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260109863-A1 | AZASILANE DETECTABLE COMPOUNDS | SINGULAR GENOMICS SYSTEMS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12539334-B2 | Phosphoalkyl polymers comprising biologically active agents | Sony Group Corporation (JP) | 2026-02-03 | — | — | US | disclosed |
| EP-0359996-A2 | Synthetic amino acid-and/or peptide-containing graft copolymers | Al Marzook United Commercial Co. (KW) | 1990-03-28 | — | — | EP | disclosed |
| US-4908404-A | Water soluble high molecular weight cationic graft polymer | BIOPOLYMERS, INC. (US) | 1990-03-13 | — | — | US | disclosed |
| US-3959190-A | ALKYL SULFIDE- CROSSLINKED POLYSTYRENE | DYNAPOL (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539334-B2 | Phosphoalkyl polymers comprising biologically active agents | EGFR, ERBB2, TK1 | MGLL 724/4885FAAH 1475/4885 |
| US-20260109863-A1 | AZASILANE DETECTABLE COMPOUNDS | BCL9L, H1-0, BCL9 | MGLL 4061/4885FAAH 1191/4885 |
| US-12629425-B2 | Progammable polymeric drugs | CHRNE, CHRND, PHOSPHO1 | MGLL 2096/4885FAAH 3139/4885 |
| US-20140350233-A1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | PHAX, RNASE1, MCTS1 | MGLL 4674/4885FAAH 4688/4885 |
| US-20120108803-A1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | PHAX, RNASE1, MCTS1 | MGLL 4674/4885FAAH 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.